PE20020657A1 - Derivados de amida de piperidinas 1,4-disustituidas de formula (i) - Google Patents

Derivados de amida de piperidinas 1,4-disustituidas de formula (i)

Info

Publication number
PE20020657A1
PE20020657A1 PE2001001266A PE2001001266A PE20020657A1 PE 20020657 A1 PE20020657 A1 PE 20020657A1 PE 2001001266 A PE2001001266 A PE 2001001266A PE 2001001266 A PE2001001266 A PE 2001001266A PE 20020657 A1 PE20020657 A1 PE 20020657A1
Authority
PE
Peru
Prior art keywords
alkyl
disustituted
amide derivatives
formula
piperidins
Prior art date
Application number
PE2001001266A
Other languages
English (en)
Inventor
Guihua Guo
Zhaoning Zhu
Yuanzan Ye
Brian A Mckittrick
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20020657A1 publication Critical patent/PE20020657A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A DERIVADOS DE AMIDA DE PIPERIDINAS 1,4-DISUSTITUIDAS DE FORMULA I DONDE R1 ES R5-CICLOALQUILO C3-C8, R5 ES CICLOALQUILO(C3-C8) ALQUILO(C1-C6), R5-ARILO ENTRE OTROS; R2 ES H, ALQUILO C1-C6, R6-CICLOALQUILO(C3-C8), R6-HETEROCICLOALQUILO, ENTRE OTROS; R3 ES ALQUILO C1-C6, CH2OH; R4 ES H, ALQUILO C1-C6; R5 ES H, ALQUILO C1-C6, HALOGENO, OH, ALCOXI C1-C6, ENTRE OTROS; R6 ES H, ALQUILO C1-C6, HALOGENO, ENTRE OTROS. UN COMPUESTO PREFERIDO ES EL GRUPO a. LOS DERIVADOS DE AMIDA DE PIPERIDINAS 1,4-DISUSTITUIDAS SON ANTAGONISTAS MUSCARINICOS UTILES PARA TRATAR TRASTORNOS COGNITIVOS COMO ALZHEIMER
PE2001001266A 2000-12-22 2001-12-18 Derivados de amida de piperidinas 1,4-disustituidas de formula (i) PE20020657A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25785300P 2000-12-22 2000-12-22

Publications (1)

Publication Number Publication Date
PE20020657A1 true PE20020657A1 (es) 2002-07-23

Family

ID=22978046

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001001266A PE20020657A1 (es) 2000-12-22 2001-12-18 Derivados de amida de piperidinas 1,4-disustituidas de formula (i)

Country Status (15)

Country Link
US (1) US6458812B1 (es)
EP (1) EP1343760B1 (es)
JP (2) JP4012068B2 (es)
CN (1) CN1481360A (es)
AR (1) AR035612A1 (es)
AT (1) ATE439344T1 (es)
AU (1) AU2002235224A1 (es)
CA (1) CA2431952C (es)
DE (1) DE60139571D1 (es)
ES (1) ES2329975T3 (es)
HK (1) HK1054391A1 (es)
MX (1) MXPA03005743A (es)
MY (1) MY133992A (es)
PE (1) PE20020657A1 (es)
WO (1) WO2002051808A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) * 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
AU2005289808B2 (en) * 2004-09-24 2011-11-03 The Government Of The United States As Represented By The Secretary Of The Army, U.S. Army Medical Research Institute Of Chemical Defense Method of treating organophosphorous poisoning
US9132135B2 (en) * 2004-09-24 2015-09-15 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
US7678116B2 (en) 2004-12-06 2010-03-16 Dfine, Inc. Bone treatment systems and methods
US7559932B2 (en) * 2004-12-06 2009-07-14 Dfine, Inc. Bone treatment systems and methods
US7722620B2 (en) 2004-12-06 2010-05-25 Dfine, Inc. Bone treatment systems and methods
CN101198595A (zh) * 2005-06-14 2008-06-11 先灵公司 天冬氨酰基蛋白酶抑制剂
US7812013B2 (en) * 2005-06-14 2010-10-12 Schering Corporation Macrocyclic heterocyclic aspartyl protease inhibitors
BRPI0612545A2 (pt) 2005-06-14 2010-11-23 Schering Corp compostos inibidores de protease, composições farmacêuticas e uso dos mesmos
KR20080029965A (ko) 2005-06-14 2008-04-03 쉐링 코포레이션 아스파르틸 프로테아제 억제제
DE602006018456D1 (de) 2005-06-14 2011-01-05 Schering Corp Herstellung und verwendung von verbindungen als aspartylproteasehemmer
US20080027456A1 (en) * 2006-07-19 2008-01-31 Csaba Truckai Bone treatment systems and methods
US8696679B2 (en) 2006-12-08 2014-04-15 Dfine, Inc. Bone treatment systems and methods
WO2008073370A1 (en) * 2006-12-12 2008-06-19 Schering Corporation Aspartyl protease inhibitors containing a tricyclic ring system
MX2009006228A (es) 2006-12-12 2009-06-22 Schering Corp Inhibidores de aspartil proteasa.
WO2008137428A2 (en) 2007-04-30 2008-11-13 Dfine, Inc. Bone treatment systems and methods
WO2009032277A1 (en) 2007-09-06 2009-03-12 Schering Corporation Gamma secretase modulators
US8487099B2 (en) 2007-11-05 2013-07-16 Merck Sharp & Dohme Corp. Gamma secretase modulators
MX2010006378A (es) * 2007-12-11 2010-09-07 Schering Corp Moduladores de gamma secretasa.
CA2742486A1 (en) 2008-11-13 2010-05-20 Schering Corporation Gamma secretase modulators
TW201034666A (en) 2008-12-22 2010-10-01 Schering Corp Gamma secretase modulators
CA2747750A1 (en) 2008-12-22 2010-07-01 Theodros Asberom Gamma secretase modulators
US20120010264A1 (en) * 2009-03-26 2012-01-12 Dainippon Sumitomo Pharma Co., Ltd. Novel medicament for treating cognitive impairment
US20120245158A1 (en) 2009-06-16 2012-09-27 Xianhai Huang Gamma secretase modulators
EP2443118A1 (en) 2009-06-16 2012-04-25 Schering Corporation Gamma secretase modulators
EP2443121A2 (en) 2009-06-16 2012-04-25 Schering Corporation Gamma secretase modulators
US20110281853A1 (en) 2010-05-12 2011-11-17 Rishi Arora Compositions and methods for treating or preventing atrial fibrillation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04312572A (ja) * 1991-04-12 1992-11-04 Takeda Chem Ind Ltd 環状アミン化合物
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
TW542822B (en) * 1997-01-17 2003-07-21 Ajinomoto Kk Benzamidine derivatives
US6066636A (en) * 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists

Also Published As

Publication number Publication date
CA2431952A1 (en) 2002-07-04
CN1481360A (zh) 2004-03-10
US6458812B1 (en) 2002-10-01
ES2329975T3 (es) 2009-12-03
JP2004516313A (ja) 2004-06-03
EP1343760B1 (en) 2009-08-12
MY133992A (en) 2007-11-30
EP1343760A2 (en) 2003-09-17
JP2007297410A (ja) 2007-11-15
MXPA03005743A (es) 2003-09-05
CA2431952C (en) 2010-03-09
WO2002051808A3 (en) 2003-01-23
AR035612A1 (es) 2004-06-16
DE60139571D1 (de) 2009-09-24
ATE439344T1 (de) 2009-08-15
HK1054391A1 (zh) 2003-11-28
JP4012068B2 (ja) 2007-11-21
AU2002235224A1 (en) 2002-07-08
WO2002051808A2 (en) 2002-07-04

Similar Documents

Publication Publication Date Title
PE20020657A1 (es) Derivados de amida de piperidinas 1,4-disustituidas de formula (i)
PE20030809A1 (es) Derivados de piperidina como antagonistas de la hormona concentradora de la melanina (mch)
PE20001467A1 (es) Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina
PE20021005A1 (es) Quinazolinas como inhibidores de mmp-13
ECSP045317A (es) Piridinoilpiperidinas como agonistas de 5-ht1f
PE20091621A1 (es) Derivados de amina como moduladores de la actividad de tlr y composiciones que los contienen
PE20060483A1 (es) Compuestos heterociclicos como antagonistas de nk1
PE20011228A1 (es) Derivados de piridopirimidina o iminopirimidina utiles para el tratamiento de enfermedades neurodegenerativas
PE20051039A1 (es) [1,8] naftiridin-2-onas y compuestos relacionados
PE20050482A1 (es) Derivados de dihidrobenzofuranilo alcanamida
PE20020298A1 (es) Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona como antagonistas de receptores de neuroquinina nk-1
HRP20030003B1 (en) N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
PE20021002A1 (es) Compuestos heterociclicos condensados
YU8703A (sh) Derivati 4-fenil-piridina kao antagonisti receptora neurokinina-1
AR006720A1 (es) Un compuesto derivado de azahexano heterociclico, su uso para la preparacion de una composicion farmaceutica, procedimiento para prepararlo y una composicion farmaceutica que lo comprende
PE20061144A1 (es) DERIVADOS DE PIRROLIDINA Y PIPERIDINA ACETILENO COMO ANTAGONISTAS DE LOS RECEPTORES DE GLUTAMATO METABOTROPICO (mGluRs)
PE20020721A1 (es) Derivados de quinuclidina como agentes antimuscarinicos m3
PE20011233A1 (es) Compuestos alquil aminoazepan-3-ona como inhibidores de proteasas
ES2193607T3 (es) Derivados de benzosulfona .
PE20030134A1 (es) Derivados de oxazolidinonas como antibacterianos
PE20021004A1 (es) Derivados de piperidina como inhibidores de la ccr5
PE20040757A1 (es) Derivados de benzoxazina
PE20191784A1 (es) Compuestos inhibidores de vmat2, composiciones y metodos relativos a los mismos
AR034585A1 (es) Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos
PA8575001A1 (es) Fluorobenzamidas como inhibidores de maob

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed